Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 1100
Summary
- Conditions
- Bile Duct Cancer
- Advanced Cancer
- Endometrial Carcinoma
- Small Cell Lung Cancer (SCLC)
- Advanced Solid Tumors
- Anal Cancer
- Anal Carcinoma
- Biliary Cancer
- Parotid Gland Cancer
- Salivary Gland Carcinoma
- Thyroid Carcinoma
- Endometrial Cancer
- Salivary Cancer
- Vulvar Cancer
- Carcinoid Tumor
- Cervical Cancer
- Thyroid Cancer
- Cervical Carcinoma
- Cholangiocarcinoma
- Mesothelioma
- Small Cell Lung Carcinoma
- Vulvar Carcinoma
- Neuroendocrine Tumor
- Colorectal Carcinoma
- Salivary Gland Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02628067
- Collaborators
- Not Provided
- Investigators
- Study Director: Medical Director Merck Sharp & Dohme Corp.
Get Well Soon